Literature DB >> 27373513

Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.

Martina Gambato1, Sofía Pérez-Del-Pulgar1, Charlotte Hedskog2, Evguenia S Svarovskia2, Diana Brainard2, Jill Denning2, Michael P Curry3, Michael Charlton4, Noelia Caro-Pérez1, Maria Carlota Londoño1, George Koutsoudakis1, Xavier Forns5.   

Abstract

We assessed the presence of hepatitis C virus (HCV) RNA in liver explants from 39 patients awaiting liver transplantation who were treated with an interferon-free regimen and had undetectable serum HCV RNA at the time of liver transplantation. Interestingly, HCV RNA was detected in most liver explants (67%). Patients with HCV RNA-positive explants had received shorter courses of treatment, and HCV RNA was undetectable in serum for shorter periods before transplantation compared to patients with HCV RNA-negative explants (P = .014 and P = .013, respectively). Levels of HCV RNA in explants were significantly higher in patients with a relapse of HCV infection than patients who responded to treatment (P = .016), but most patients (85%) with residual HCV-RNA in the explant achieved a sustained virologic response after receiving their liver transplant.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DAA; IFN-free; SVR; Viral Persistence

Mesh:

Substances:

Year:  2016        PMID: 27373513     DOI: 10.1053/j.gastro.2016.06.025

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation.

Authors:  Ilaria Lenci; Alessandra Bosa; Martina Milana; Leonardo Baiocchi; Francesco Paolo Antonucci; Marianna Aragri; Francesca Ceccherini-Silberstein; Carlo Federico Perno; Giuseppe Tisone; Mario Angelico
Journal:  Dig Dis Sci       Date:  2017-05-12       Impact factor: 3.199

2.  According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.

Authors:  Elia Moreno-Cubero; Dolores Subirá; Eduardo Sanz-de-Villalobos; Trinidad Parra-Cid; Antonio Madejón; Joaquín Miquel; Antonio Olveira; Alejandro González-Praetorius; Javier García-Samaniego; Juan-Ramón Larrubia
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

3.  Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.

Authors:  Sandra Elmasry; Sanya Wadhwa; Bo-Ram Bang; Linda Cook; Shefali Chopra; Gary Kanel; Brian Kim; Tammy Harper; Zongdi Feng; Keith R Jerome; Jeffrey A Kahn; Takeshi Saito
Journal:  Gastroenterology       Date:  2016-11-09       Impact factor: 22.682

Review 4.  Management of Cirrhotic Patients After Successful HCV Eradication.

Authors:  Ryan M Kwok; Tram T Tran
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

5.  Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.

Authors:  Yijin Wang; Huiying Rao; Xiumei Chi; Boan Li; Hongyang Liu; Liyuan Wu; Hao Zhang; Shuhong Liu; Gaungde Zhou; Na Li; Junqi Niu; Lai Wei; Jingmin Zhao
Journal:  EBioMedicine       Date:  2019-07-23       Impact factor: 8.143

Review 6.  Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Authors:  Thomas F Baumert; Frank Jühling; Atsushi Ono; Yujin Hoshida
Journal:  BMC Med       Date:  2017-03-14       Impact factor: 11.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.